ERBB2 and cancer: A 2022 study of 33,976 women with metastatic breast cancer found that Hispanic women were more likely to be HER2‐negative than HER2‐positive (31% vs. 28%, p < 0.01); this study did not differentiate between HER2‐low and fully HER2‐negative cancers.15